olmutinib
Small moleculeexperimental
Olmutinib (INN) is an investigational anti-cancer drug. It acts by covalently bonding to a cysteine residue near the kinase domain of epidermal growth factor receptor (EGFR). — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 17, 2017 (NCT03228277)
Timeline
Indications
Studied for
Mechanism of action
EGFR inhibitor
EGFR mutant selective including both activating mutations and T790M (PMID: 26508839)
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1- Mol. weight
- 486.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3786343 ↗
- WikipediaOlmutinib ↗
Also known as
- olmutinib
- olmutinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04510415 | Phase 1 | Mar 29, 2018 | Hanmi Pharmaceutical |
| NCT03228277 | Phase 2 | Jul 17, 2017 | Hanmi Pharmaceutical, Konkuk University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 2 | 1 | 2 | 2017 |
| Konkuk University | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1